Morria Biopharmaceuticals Plc. Obtains Institutional Review Board Clearance To Conduct Phase II Study In Contact Dermatitis Patients Using MRX6

Main Category: Dermatology
Also Included In: Clinical Trials / Drug Trials
Article Date: 26 Aug 2009 - 6:00 PDT

email to a friend   printer friendly   opinions  

Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6. The double-blind, placebo-controlled study on 80 contact dermatitis patients will take place at the Hadassah Hospital in Israel. A previous pilot clinical study demonstrated that a topical preparation of MRX6, applied for 28 days (b.i.d), scored 69% improvement based on conventional Physician's Assessment. The upcoming study will examine a 21 days (b.i.d) regime and monitor pharmacokinetics and dose-response parameters.

"This upcoming trial marks an important milestone for Morria's unique proprietary technology", said Dr. Yuval Cohen, President of Morria Biopharmaceuticals Plc. "Our aim is to continue expanding in the inflammatory skin disease area as well as accelerate our parallel program in the respiratory field such as allergic rhinitis and cystic fibrosis, and in gastro-intestinal inflammation. We expect more clinical trial in these fields to commence in the near future. These programs demonstrate the potent transformative application of our technology."

About Contact Dermatitis

Contact dermatitis is an allergic condition in which patients develop skin reactions when coming into contact with certain materials/substances such as metals, latex and fabrics. The market for this condition is estimated at $600m.

Source
Morria Biopharmaceuticals Plc

• Additional
• References
• Citations